Janux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. Buys 110,206 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. bought 110,206 shares of the business’s stock in a transaction dated Friday, March 7th. The stock was acquired at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the purchase, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. The trade was a 1.10 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, March 5th, Ra Capital Management, L.P. bought 341,742 shares of Janux Therapeutics stock. The stock was acquired at an average price of $30.64 per share, for a total transaction of $10,470,974.88.

Janux Therapeutics Price Performance

Shares of JANX stock opened at $30.64 on Friday. The company’s fifty day simple moving average is $41.74 and its two-hundred day simple moving average is $47.55. Janux Therapeutics, Inc. has a 1 year low of $29.63 and a 1 year high of $71.71. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -26.19 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of JANX. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Janux Therapeutics in the fourth quarter worth $2,477,000. GF Fund Management CO. LTD. bought a new position in shares of Janux Therapeutics during the fourth quarter valued at about $59,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Janux Therapeutics by 532.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 165,737 shares of the company’s stock worth $8,874,000 after buying an additional 139,543 shares in the last quarter. Woodline Partners LP raised its stake in Janux Therapeutics by 15.7% in the fourth quarter. Woodline Partners LP now owns 1,852,187 shares of the company’s stock worth $99,166,000 after buying an additional 251,924 shares in the last quarter. Finally, Squarepoint Ops LLC raised its stake in Janux Therapeutics by 155.1% in the fourth quarter. Squarepoint Ops LLC now owns 41,176 shares of the company’s stock worth $2,205,000 after buying an additional 25,034 shares in the last quarter. Institutional investors own 75.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Leerink Partners boosted their target price on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $200.00 target price on shares of Janux Therapeutics in a research note on Wednesday, December 11th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Scotiabank lowered their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Janux Therapeutics in a report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $88.00.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.